---
title: "A Hangzhou startup is betting brain-computer interface means a sleep patch, not an implant"
date: 2026-11-12
category: Brain–Computer Interface
site: NeuroAI
canonical: https://neuroai.site/a/na-brain-flexolink-sleep
language: en
---

# A Hangzhou startup is betting brain-computer interface means a sleep patch, not an implant

> Flexolink, a Hangzhou non-invasive BCI company, built a flexible EEG sleep monitor that earned a Chinese Class II medical-device registration and showed at CES 2025 — the soft side of China's brain-tech push.

Most of the brain-computer interface (脑机接口) conversation is loud: electrodes drilled into skulls, paralyzed patients moving cursors with thought, billion-dollar valuations.

Quietly, a different version is being stuck to people's foreheads while they sleep.

The patch is thin, flexible, and made to be forgotten by morning. No surgery, no clinic, no neurosurgeon. Just a strip of sensor reading brain waves all night — and a Hangzhou company arguing that this, not the implant, may be where brain-computer interface (BCI) first reaches ordinary homes.

## Key takeaways

- Flexolink (柔灵科技 / FlectoThink), founded in Hangzhou in March 2020, builds non-invasive (非侵入式) BCI products built on flexible EEG electrodes.

- Its brain-wave sleep monitor BM01 obtained a Chinese Class II medical-device registration certificate in 2023 (registration No. 粤械注准20232070995).

- The company exhibited at CES 2025 in the Zhejiang provincial pavilion, showing consumer and clinical sleep products.

- Flexolink has raised outside capital including a 2022 round of about RMB 11 million (≈ US$1.5M / HK$12M) from Dunhong Capital, and was recognized as a national high-tech enterprise in 2024.

## The patch, not the probe

Flexolink's core idea is that useful brain signals do not always require opening the skull. Its flagship medical-grade product, the brain-wave sleep monitor BM01, is a single-channel forehead patch using a flexible nano-electrode. The company states the device is about 18 grams, slim enough to wear through the night, and runs 12-plus hours on one charge while capturing EEG and motion data.

Paired software turns that signal into a sleep-stage report aligned with the AASM (American Academy of Sleep Medicine) standard, the same framework used in clinical sleep labs. The manufacturer says its readings correlate 83–93% with gold-standard polysomnography (PSG) — a claim we could not independently verify against published validation, so treat it as the company's own statement.

## Why sleep is the proving ground

Sleep is an unusually good first market for non-invasive BCI. The signal is rich, the user is stationary, and the stakes of a wrong reading are low enough that a consumer device can iterate in homes rather than only in hospitals. Flexolink also sells a forehead-mounted "sleep aid" unit (BM05) that links the brain signal to sound-based closed-loop intervention — playing specific frequencies when it detects light or fragmented sleep.

Founder Sun Yu (孙瑜), a polymer-science PhD from the University of Akron who returned to China after running a U.S. consulting firm for twelve years, has framed the strategy as "monitor first, intervene second." The company also reports pilots connecting the patch to IoT (物联网) home devices — lights, speakers, climate — to build what it calls a "sleep space" steered by brain state.

## From lab to CES

Flexolink set up in Hangzhou's Zhejiang University computing-research incubator in 2020 and opened a hardware R&D center in Shenzhen, with additional offices abroad including Atlanta. At CES 2025, the Zhejiang provincial trade body featured the company in its "Zhejiang Quality Products" showcase, presenting both the consumer sleep unit and the medical-grade monitor.

The Class II registration is the piece that separates a gadget from a medical claim. A Class II certificate in China covers devices of moderate risk with established safety methods; it is not the stricter Class III pathway used for implantable brain stimulators. For Flexolink, the certificate lets the BM01 be positioned as a medical-grade sleep-monitoring tool rather than a wellness toy.

## The money and the recognition

Flexolink's funding history, per the company, runs from an angel round in 2021 led by Zhejiang University Holdings and related funds, to a 2022 investment of about RMB 11 million (≈ US$1.5M / HK$12M) from Dunhong Capital, to a multi-ten-million-yuan Pre-A in 2023 led by Shanghai Lanwan. It was named a national high-tech enterprise in late 2024 and, the company says, was one of ten representative small firms invited to a 2025 roundtable chaired by China's minister of industry and information technology.

## Honest limitations

- Hard performance figures (18 g, 83–93% PSG correlation, accuracy percentages) come from the manufacturer or product listings; we found no independently published validation study to confirm them.

- The Class II registration certifies the device as a moderate-risk medical monitor in China; it is not an approval for diagnosing or treating any disease, and we did not verify overseas regulatory status.

- Financing amounts and the roundtable invitation are company-reported; we did not access term sheets or government attendance records.

- This article covers one company's non-invasive consumer-medical path and does not assess the larger field of sleep wearable competitors.

## What readers can do now

- If you are shopping for a sleep tracker, check whether a device holds a valid medical-device registration in your market and what that registration actually permits — monitoring is not the same as diagnosis.

- Treat any "medical-grade" brain-wave claim as provisional until you see published validation against polysomnography from an independent lab.

- For persistent sleep problems, use a consumer patch as a lifestyle signal, not a substitute for a clinician's evaluation and, if needed, a supervised sleep study.

---

Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-flexolink-sleep
Free to quote with attribution and a link to the original.
